SHANGHAI, China, July 19, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (鈥淛unshi Biosciences,鈥 HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application for toripalimab, the company鈥檚 anti-PD-1 monoclonal antibody, in combination with etoposide plus platinum for the first-line treatment of patients with extensive-stage small cell lung cancer (鈥淓S-SCLC鈥?, has been accepted for review by the National Medical Products Administration (鈥淣MPA鈥?.